Wuhan YZY Biopharma Co., Ltd. (YZYBIO-B) disclosed its Monthly Return on Movements in Securities for March 2026, highlighting the completion of its H-share full-circulation programme and a material shift in share class composition.

Key developments

1. Full-circulation conversion • On 30 March 2026, 61.14 million unlisted domestic shares and 6.87 million unlisted foreign shares—together totalling 68.01 million shares—were successfully converted into H shares. • Post-conversion, unlisted foreign shares were fully eliminated, and domestic shares contracted to 14.37 million.

2. Authorised and issued share capital • Authorised/registered share capital increased by 68.01 million shares to 193.85 million shares (par value RMB 1 each). • Issued H shares expanded 61.02 % month-on-month, from 111.47 million to 179.48 million. • Aggregate issued share capital now stands at 193.85 million shares, split into: – H shares: 179.48 million (92.59 % of total) – Domestic shares: 14.37 million (7.41 % of total) – Unlisted foreign shares: nil • The company reported zero treasury shares.

3. Public-float status YZYBIO-B confirmed compliance with the Main Board’s 25 % minimum public-float requirement as at 31 March 2026.

4. Share-based incentive update Under the 2024 H Share Option Plan (adopted 27 June 2024), 1.25 million options remained outstanding at month-end. A potential 312,500 new H shares could be issued upon future exercises, while the scheme’s total reserve allows for up to 18.13 million shares.

Context and implication

The completed full-circulation scheme significantly increases the tradable portion of YZYBIO-B’s equity on the Hong Kong Stock Exchange, broadening investor access and enhancing liquidity. With over 92 % of its shares now in H-share form and public-float compliance confirmed, the company has bolstered its capital market profile ahead of future financing or strategic initiatives.